ADVERTISEMENT

If you are seeing this message, you may be experiencing temporary network problems. Please wait a few minutes and refresh the page. If the problem persists, you may wish to report it to your local Network Manager.

It is also possible that your web browser is not configured or not able to display style sheets. In this case, although the visual presentation will be degraded, the site should continue to be functional. We recommend using the latest version of Microsoft or Mozilla web browser to help minimise these problems.

Wiley InterScience

< Previous Abstract  |  Next Abstract >

Save Article to My Profile      Download Citation      Request Permissions

Abstract |  References  |  Full Text: HTML, PDF (Size: 104K)  | Related Articles | Citation Tracking

Simplified bladder training augments the effectiveness of tolterodine in patients with an overactive bladder
A. Mattiasson , J. Blaakaer*, K. Høye, A.J. Wein and The Tolterodine Scandinavian Study Group
  Department of Urology, University Hospital, Lund, Sweden,   * Department of Obstetrics and Gynaecology, Skejby Hospital, Aarhus, Denmark,   Helsetorget Legesenter, Elverum, Norway, and   Division of Urology, University of Pennsylvania Medical Center, Philadelphia, USA
Correspondence: Professor Anders Mattiasson, Department of Urology, University Hospital, 221 85 Lund, Sweden.
e-mail: anders.mattiasson@urokir.lu.se
Copyright BJU International
KEYWORDS
overactive bladder • tolterodine • bladder training

ABSTRACT

 
OBJECTIVES

To compare the efficacy of tolterodine plus simplified bladder training (BT) with tolterodine alone in patients with an overactive bladder.

 
PATIENTS AND METHODS

In a multicentre, single-blind study at 51 Scandinavian centres, 505 patients aged ≥ 18 years with symptoms of urinary frequency (≥ 8 micturitions/24 h) and urgency, with or without urge incontinence, were randomized to oral treatment with either tolterodine 2 mg twice daily plus simplified BT or tolterodine alone. Changes in voiding diary variables were evaluated after 2, 12 and 24 weeks of treatment. The patients' perceptions of their bladder symptoms and tolerability (adverse events) were also determined.

 
RESULTS

In all, 501 patients (75% women) were evaluable on an intention-to-treat basis (244 on tolterodine + BT and 257 on tolterodine alone). Tolterodine significantly reduced the voiding frequency and increased the volume voided per void at all sample times; these effects were significantly increased by adding BT. At the end of the study the median percentage reduction in voiding frequency was greater with tolterodine + BT than with tolterodine alone (33% vs 25%, P < 0.001), while the median percentage increase in volume voided per void was 31% with tolterodine + BT and 20% with tolterodine alone (P < 0.001). There was a median of 81% fewer incontinence episodes than at baseline with tolterodine alone, which was not significantly different from that with tolterodine + BT (− 87%). The two groups had comparable median percentage reductions in urgency episodes. Some 76% of patients on tolterodine + BT reported an improvement in their bladder symptoms relative to baseline, compared with 71% on tolterodine alone. Tolterodine was well tolerated; the most common adverse event was mild dry mouth.

 
CONCLUSION

Tolterodine 2 mg twice daily is an effective and well tolerated treatment for an overactive bladder, the effectiveness of which can be augmented by a simplified BT regimen.


Accepted for publication 27 September 2002

DIGITAL OBJECT IDENTIFIER (DOI)
10.1046/j.1464-410X.2003.03076.x About DOI

Related Articles

  • Find other articles like this in Wiley InterScience
  • Find articles in Wiley InterScience written by any of the authors

Wiley InterScience is a member of CrossRef.

Cross Ref Member


Click here
Click Here